# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitations of Current CAH Treatment Paradigm in Children, Adolescents ...
Evercore ISI Group analyst Cory Kasimov initiates coverage on Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform rating ...
CAHtalyst™ Study Baseline Characteristics Highlight the Need for New Treatment Options to Reduce Adrenal Androgens and Supraphy...
Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) notes that its partner Neurocrine Biosciences Inc. (("Ne...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to eval...
CAHtalyst™ Pediatric and CAHtalyst™ Adult Baseline Characteristics Data in Congenital Adrenal HyperplasiaPhase 2 (CHAMPAIN) Cli...
Citigroup analyst David Hoang maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Neutral and raises the price target from...
Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price tar...
Guggenheim analyst Yatin Suneja maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $...